Venture Funding Deals, February 2015
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced December 2014 through January 2015.
You may also be interested in...
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
The company agreed to pay $60m upfront to buy privately-held RetroSense, the developer of a novel gene therapy in Phase I/II clinical testing for retinitis pigmentosa. The investment in early R&D helps Allergan catch up with other eye care research.
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.
Financing Quarterly Statistics, Q3 2021
For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.